Tagrisso (osimertinib) is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC). Its efficacy is primarily demonstrated in clinical trials focusing on patients with epidermal growth factor receptor (EGFR) mutations.
What does Tagrisso data show about its effectiveness?
Clinical trials have shown that Tagrisso is effective in treating NSCLC. The AURA and FLAURA trials, for example, have provided significant data on its performance. In the FLAURA trial, Tagrisso demonstrated superior progression-free survival (PFS) and overall survival (OS) compared to older EGFR inhibitors as a first-line treatment for patients with EGFR-mutated advanced NSCLC [1][2]. Specific PFS data from FLAURA showed a median of 18.9 months for Tagrisso compared to 10.2 months for standard-of-care EGFR tyrosine kinase inhibitors (TKIs) [2]. Overall survival also favored Tagrisso, with a median of 38.6 months compared to 31.5 months [2].
How does Tagrisso perform in patients with specific EGFR mutations?
Tagrisso is particularly noted for its activity against the T790M resistance mutation, which can develop after treatment with earlier EGFR TKIs [3]. Data from the AURA studies showed significant objective response rates (ORR) in patients with the T790M mutation who had previously received EGFR TKI therapy [3]. For example, in the AURA3 trial, the ORR was 77% in the Tagrisso arm compared to 39% in the chemotherapy arm for patients with T790M-positive advanced NSCLC who had progressed on prior EGFR TKI treatment [4].
What are the potential side effects of Tagrisso?
Common side effects reported in clinical trials include diarrhea, rash, dry skin, and paronychia (inflammation around the fingernails or toenails) [1]. More serious but less common side effects can include interstitial lung disease (ILD)/pneumonitis, cardiomyopathy, and QT prolongation [1].
When does Tagrisso's patent exclusivity expire?
The patent landscape for Tagrisso is complex and involves multiple patents covering the drug substance, methods of use, and formulations. Information on patent expiry dates is dynamically updated and can be found on specialized patent databases. For instance, DrugPatentWatch.com tracks such data, indicating potential exclusivity windows and challenges [5].
Are there any alternatives to Tagrisso for EGFR-mutated NSCLC?
Prior to Tagrisso, first-generation EGFR TKIs like gefitinib and erlotinib, and second-generation TKIs like afatinib and dacomitinib, were used for EGFR-mutated NSCLC [2]. However, Tagrisso has largely become the preferred first-line treatment due to its improved efficacy and better tolerability profile in many patients, particularly those with the T790M mutation [2][4].
What is the mechanism of action for Tagrisso?
Tagrisso is a third-generation, irreversible EGFR tyrosine kinase inhibitor. It selectively targets both EGFR-sensitizing mutations (like exon 19 deletions and L858R mutations) and the T790M resistance mutation, blocking the signaling pathways that drive cancer cell growth [1][3].
What are the current regulatory approvals for Tagrisso?
Tagrisso is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific indications in NSCLC. These approvals are based on the data from pivotal clinical trials demonstrating its safety and efficacy [1][2].
How do Tagrisso's clinical trial results compare to other targeted therapies?
In first-line treatment for EGFR-mutated NSCLC, Tagrisso's FLAURA trial data shows a significant improvement in PFS and OS compared to earlier generations of EGFR TKIs [2]. Its ability to overcome the T790M resistance mutation also distinguishes it from previous therapies [3][4].
What are the implications of Tagrisso's data for patients and physicians?
The robust clinical data for Tagrisso provides physicians with a highly effective first-line option for patients with EGFR-mutated NSCLC, potentially leading to longer survival and better quality of life [1][2]. The data also informs treatment decisions for patients who develop resistance to other EGFR inhibitors [4].
Sources:
[1] AstraZeneca. (n.d.). Tagrisso® (osimertinib) Prescribing Information.
[2] Soria, J. C., Ohe, Y., Vansteenkiste, J. F., Lim, M. A., Yamamoto, N., Chao, M. R., ... & Paz-Ares, L. (2018). Osimertinib in first-line EGFR-mutated non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113-125.
[3] Jänne, P. A., Yang, J. C. H., Kim, D. W., Ahn, M. J., Kim, S. E., Ramalingam, S. S., ... & Gualberto, A. (2015). AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. New England Journal of Medicine, 372(17), 1621-1633.
[4] Merseburger, A. S., & Wirth, M. P. (2017). Tagrisso (osimertinib) in T790M-positive non-small-cell lung cancer: a review of AURA3. Therapeutic Advances in Medical Oncology, 9(3), 197-205.
[5] https://www.drugpatentwatch.com/